ArticleGut1996
Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers.
Article in Gut, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 101 citations in OpenAlex.
- Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease.Gut · 2001Trial
- Exposure to structurally unique β-d-glucans differentially affects inflammatory responses in male mouse lungs.Physiological reports · 2024Article
- IL-10 Deficiency Accelerates Type 1 Diabetes DevelopmentFrontiers in immunology · 2021Article
- Intestinal epithelial HMGB1 inhibits bacterial infection via STAT3 regulation of autophagy.Autophagy · 2019Article
- Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells.The Journal of clinical investigation · 2019Article
- Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis.Gut · 2015Article
- Fungal exposure and low levels of IL-10 in patients with sarcoidosis.Pulmonary medicine · 2014Article
- Oral treatment with Hev b 13 ameliorates experimental colitis in mice.Clinical and experimental immunology · 2012Article
- In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.Clinical and experimental immunology · 2011Article
- Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice.Gastroenterology · 2011Article
- Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.Inflammatory bowel diseases · 2011Review
- Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.Digestive diseases and sciences · 2010Review
- Gatekeepers of intestinal inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010Review
- Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.Journal of inflammation (London, England) · 2005Article
- Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis.Immunology · 2005Article
- Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity.The Journal of clinical investigation · 2005Article
- Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats.Clinical and experimental immunology · 2004Article
- Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50.Clinical and experimental immunology · 2004Article
- Transfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1.BMC gastroenterology · 2003Article
- Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats.Clinical and experimental immunology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsInterleukin 10 (IL10) inhibits monocyte/macrophage and T lymphocyte effector functions. This study examined the effect of systemically administered IL10 on acute and chronic granulomatous enterocolitis, hepatitis, and arthritis in a rat model.
methodsLewis rats were injected intramurally with streptococcal peptidoglycan-polysaccharide (PG-APS) polymers. Beginning 12 hours before PG-APS injection, rats were treated daily with subcutaneous murine recombinant IL10 or vehicle for three or 17 days.
resultsIL10 attenuated acute enterocolitis in a dose dependent fashion (p < 0.01). Protective effects were more profound in the chronic granulomatous phase with decreased enterocolitis and markedly inhibited leucocytosis, hepatic granulomas, and chronic erosive arthritis (p < 0.001). IL10 downregulated tissue IL1, IL6, tumour necrosis factor alpha, and interferon gamma gene expression, consistent with the in vitro effects of IL10 on PG-APS-stimulated splenocytes. Caecal IL1 protein concentrations and IL2 and interferon gamma secretion by in vitro stimulated mesenteric lymph nodes were downregulated in IL10 treated animals.
conclusionsThese results indicate that exogenous IL10 can inhibit experimental granulomatous inflammatory responses and suggest that IL10 treatment could be an effective new therapeutic approach in human disorders such as Crohn's disease, rheumatoid arthritis, and sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.